46th Annual Meeting of the European Association for the Study of the Liver (EASL 2011)

March 30 - April 3, 2011, Berlin, Germany

Back EASL 2011

EASL 2011: Kidney Function in HIV/HBV Coinfected People on Tenofovir

Impaired kidney function among people with HIV, HBV, and HIV/HBV coinfection taking tenofovir mainly occurred in those with pre-existing risk factors, researchers reported at EASL 2011. alt

Read more:

Boosted Danoprevir Improves Response in Prior Null Responders

Nearly 90% of genotype 1b prior non-responder hepatitis C patients treated with ritonavir-boosted danoprevir plus pegylated interferon/ribavirin experienced early virological response at week 12, but breakthrough reached 50% for those with genotype 1a. alt

Read more:

EASL 2011: Pegylated Interferon Lambda Boosts Response with Few Side Effects

Hepatitis C patients taking an experimental interferon formulation -- pegylated interferon lambda -- had higher rates of rapid and early virological response, with fewer flu-like symptoms and blood cell deficiencies, according to a report at EASL 2011.

Read more:

EASL 2011: Monoclonal Antibody Bavituximab Well-Tolerated by HIV/HCV Coinfected People

An experimental monoclonal antibody that inhibits HCV replication was safe and well-tolerated in a clinical trial of HIV positive people coinfected with chronic hepatitis C, researchers reported at EASL 2011.

Read more:

EASL 2011: Once-Daily BI 201335 Ups Response to Interferon for Hepatitis C

Boerhinger Ingelheim's experimental HCV protease inhibitor BI 201335 added to pegylated interferon and ribavirin improved sustained response rates for both treatment-naive and treatment-experienced genotype 1 patients, researchers reported at EASL 2011. alt

Read more: